MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ALGS has $64,558K in assets. $32,769K in debts. $29,980K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
255.68%
Quick Ratio
255.68%
Cash Ratio
128.55%
Debt to Asset Ratio
50.76%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Short-term investments
    • Accumulated depreciation
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • 2023 common warrants liability
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
29,980 18,303 41,946 18,661
Restricted cash
174 110 110 110
Short-term investments
24,929 59,541 57,150 104,284
Other current assets
4,546 4,908 4,229 4,889
Total current assets
59,629 82,862 103,435 127,944
Operating lease right-of-use assets
2,580 3,089 3,581 4,059
Total, at cost
14,648 14,579 14,490 -
Accumulated depreciation
13,058 12,712 12,455 -
Property and equipment, net
1,590 1,867 2,035 2,063
Other assets
759 715 713 640
Total assets
64,558 88,533 109,764 134,706
Deferred revenue, current
-0 168 579
Accounts payable
7,639 3,982 4,651 3,937
Accrued liabilities
11,989 13,526 13,605 12,209
Operating lease liabilities, current
3,612 3,580 3,542 3,502
Finance lease liabilities, current
82 145 21 38
Total current liabilities
23,322 21,233 21,987 20,265
Operating lease liabilities, net of current portion
659 1,525 2,380 3,216
Finance lease liabilities, net of current portion
-0 122 122
2023 common warrants liability
8,788 12,183 13,396 9,191
Long term liability
0 47 46 46
Total liabilities
32,769 34,988 37,931 32,840
Common stock, 0.0001 par value 115,800,000 shares and 20,800,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 6,153,507 and 3,864,436 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively
9 9 9 9
Additional paid-in capital
696,583 695,269 693,689 692,220
Accumulated deficit
-665,241 -642,201 -622,320 -590,783
Accumulated other comprehensive income
438 468 455 420
Total stockholders' equity
31,789 53,545 71,833 101,866
Total liabilities and stockholders' equity
64,558 88,533 109,764 134,706
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$29,980K Short-term investments$24,929K Other current assets$4,546K Restricted cash$174K Total, at cost$14,648K Total current assets$59,629K Operating leaseright-of-use assets$2,580K Property and equipment,net$1,590K Other assets$759K Accumulated depreciation$13,058K Total assets$64,558K Total liabilities andstockholders' equity$64,558K Total liabilities$32,769K Total stockholders'equity$31,789K Accumulated deficit-$665,241K Total currentliabilities$23,322K 2023 common warrantsliability$8,788K Operating leaseliabilities, net of current...$659K Additional paid-in capital$696,583K Accumulated othercomprehensive income$438K Common stock, 0.0001par value...$9K Accrued liabilities$11,989K Accounts payable$7,639K Operating leaseliabilities, current$3,612K Finance leaseliabilities, current$82K

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. (ALGS)